Does the media favor IOVA or TGTX?

In the previous week, Iovance Biotherapeutics had 12 more articles in the media than TG Therapeutics. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 5 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 1.09 beat Iovance Biotherapeutics' score of 0.74 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to QGEN or IOVA?

In the previous week, Iovance Biotherapeutics had 8 more articles in the media than Qiagen. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 9 mentions for Qiagen. Qiagen's average media sentiment score of 1.25 beat Iovance Biotherapeutics' score of 0.74 indicating that Qiagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to APGE or IOVA?

In the previous week, Iovance Biotherapeutics had 7 more articles in the media than Apogee Therapeutics. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 10 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.30 beat Iovance Biotherapeutics' score of 0.74 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IMVT or IOVA?

In the previous week, Iovance Biotherapeutics had 12 more articles in the media than Immunovant. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 5 mentions for Immunovant. Immunovant's average media sentiment score of 1.02 beat Iovance Biotherapeutics' score of 0.74 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Iovance Biotherapeutics (IOVA) Competitors

$4.07 -0.62 (-13.22%)

Closing price 04:00 PM Eastern

Extended Trading

$4.09 +0.02 (+0.47%)

As of 07:49 PM Eastern

Compare

IOVA vs. PTGX, TGTX, QGEN, APGE, and IMVT

Should you buy Iovance Biotherapeutics stock or one of its competitors? MarketBeat compares Iovance Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Iovance Biotherapeutics include Protagonist Therapeutics (PTGX), TG Therapeutics (TGTX), Qiagen (QGEN), Apogee Therapeutics (APGE), and Immunovant (IMVT).

How does Iovance Biotherapeutics compare to Protagonist Therapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Protagonist Therapeutics (NASDAQ:PTGX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Protagonist Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	6.90	-$390.98M	-$0.95	N/A
Protagonist Therapeutics	$74.06M	118.65	-$130.15M	-$1.81	N/A

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Iovance Biotherapeutics presently has a consensus price target of $8.43, suggesting a potential upside of 107.09%. Protagonist Therapeutics has a consensus price target of $123.00, suggesting a potential downside of 9.98%. Given Iovance Biotherapeutics' higher probable upside, equities research analysts clearly believe Iovance Biotherapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

In the previous week, Iovance Biotherapeutics had 3 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 14 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.34 beat Iovance Biotherapeutics' score of 0.74 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Iovance Biotherapeutics has a net margin of -123.92% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Iovance Biotherapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Iovance Biotherapeutics on 10 of the 17 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to TG Therapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

In the previous week, Iovance Biotherapeutics had 12 more articles in the media than TG Therapeutics. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 5 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 1.09 beat Iovance Biotherapeutics' score of 0.74 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 65.95% compared to Iovance Biotherapeutics' net margin of -123.92%. TG Therapeutics' return on equity of 88.73% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
TG Therapeutics	65.95%	88.73%	43.44%

Iovance Biotherapeutics presently has a consensus target price of $8.43, suggesting a potential upside of 107.09%. TG Therapeutics has a consensus target price of $58.50, suggesting a potential upside of 12.44%. Given Iovance Biotherapeutics' higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

TG Therapeutics has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	6.90	-$390.98M	-$0.95	N/A
TG Therapeutics	$616.29M	12.92	$447.18M	$2.86	18.19

Iovance Biotherapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 8.9% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

TG Therapeutics beats Iovance Biotherapeutics on 12 of the 15 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Qiagen?

Qiagen (NYSE:QGEN) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Qiagen has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.10B	4.08	$424.88M	$1.91	21.76
Iovance Biotherapeutics	$263.50M	6.90	-$390.98M	-$0.95	N/A

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Qiagen currently has a consensus price target of $43.34, suggesting a potential upside of 4.29%. Iovance Biotherapeutics has a consensus price target of $8.43, suggesting a potential upside of 107.09%. Given Iovance Biotherapeutics' higher possible upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

In the previous week, Iovance Biotherapeutics had 8 more articles in the media than Qiagen. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 9 mentions for Qiagen. Qiagen's average media sentiment score of 1.25 beat Iovance Biotherapeutics' score of 0.74 indicating that Qiagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Qiagen has a net margin of 19.16% compared to Iovance Biotherapeutics' net margin of -123.92%. Qiagen's return on equity of 14.40% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Summary

Qiagen beats Iovance Biotherapeutics on 11 of the 17 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, Iovance Biotherapeutics had 7 more articles in the media than Apogee Therapeutics. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 10 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.30 beat Iovance Biotherapeutics' score of 0.74 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Apogee Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Apogee Therapeutics' return on equity of -32.64% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Apogee Therapeutics presently has a consensus target price of $121.25, suggesting a potential downside of 9.57%. Iovance Biotherapeutics has a consensus target price of $8.43, suggesting a potential upside of 107.09%. Given Iovance Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

Apogee Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Apogee Therapeutics has higher earnings, but lower revenue than Iovance Biotherapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Iovance Biotherapeutics	$263.50M	6.90	-$390.98M	-$0.95	N/A

Summary

Apogee Therapeutics and Iovance Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 1.9% of Immunovant shares are owned by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Immunovant has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Iovance Biotherapeutics' return on equity of -50.17% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Iovance Biotherapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Iovance Biotherapeutics	$263.50M	6.90	-$390.98M	-$0.95	N/A

Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

In the previous week, Iovance Biotherapeutics had 12 more articles in the media than Immunovant. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 5 mentions for Immunovant. Immunovant's average media sentiment score of 1.02 beat Iovance Biotherapeutics' score of 0.74 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant presently has a consensus price target of $42.11, suggesting a potential upside of 9.04%. Iovance Biotherapeutics has a consensus price target of $8.43, suggesting a potential upside of 107.09%. Given Iovance Biotherapeutics' higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

Summary

Iovance Biotherapeutics beats Immunovant on 10 of the 15 factors compared between the two stocks.

Get Iovance Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IOVA vs. The Competition

Export

Metric	Iovance Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.82B	$3.52B	$6.83B	$12.41B
Dividend Yield	N/A	3.78%	2.59%	10.11%
P/E Ratio	-4.28	7.45	281.83	23.65
Price / Sales	6.90	1,262.85	585.86	92.89
Price / Cash	N/A	89.39	69.88	58.30
Price / Book	2.31	16.79	10.93	5.84
Net Income	-$390.98M	-$12.44M	$3.49B	$336.16M
7 Day Performance	-18.44%	-1.48%	-0.30%	0.03%
1 Month Performance	-2.16%	-7.76%	-2.59%	-5.22%
1 Year Performance	58.37%	49.26%	66.21%	17.37%

Iovance Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IOVA Iovance Biotherapeutics	2.6546 of 5 stars	$4.07 -13.2%	$8.43 +107.1%	+75.7%	$1.82B	$263.50M	N/A	500	News Coverage Upcoming Earnings Gap Down
PTGX Protagonist Therapeutics	1.5316 of 5 stars	$135.56 -0.4%	$123.00 -9.3%	+153.8%	$8.72B	$46.02M	N/A	120	Positive News Upcoming Earnings
TGTX TG Therapeutics	3.3713 of 5 stars	$55.75 -0.5%	$58.50 +4.9%	+47.6%	$8.58B	$700.35M	19.49	290	Positive News Upcoming Earnings Analyst Forecast
QGEN Qiagen	3.9483 of 5 stars	$41.05 -0.8%	$43.34 +5.6%	-22.1%	$8.46B	$2.09B	21.44	5,654	Positive News Upcoming Earnings
APGE Apogee Therapeutics	1.9159 of 5 stars	$134.28 flat	$121.25 -9.7%	+257.1%	$8.31B	N/A	N/A	91	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IOVA) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. PTGX, TGTX, QGEN, APGE, and IMVT

How does Iovance Biotherapeutics compare to Protagonist Therapeutics?

Summary

How does Iovance Biotherapeutics compare to TG Therapeutics?

Summary

How does Iovance Biotherapeutics compare to Qiagen?

Summary

How does Iovance Biotherapeutics compare to Apogee Therapeutics?

Summary

How does Iovance Biotherapeutics compare to Immunovant?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. PTGX, TGTX, QGEN, APGE, and IMVT

How does Iovance Biotherapeutics compare to Protagonist Therapeutics?

Which has better valuation & earnings, IOVA or PTGX?

Do institutionals & insiders hold more shares of IOVA or PTGX?

Do analysts rate IOVA or PTGX?

Does the media prefer IOVA or PTGX?

Is IOVA or PTGX more profitable?

Which has more volatility and risk, IOVA or PTGX?

Summary

How does Iovance Biotherapeutics compare to TG Therapeutics?

Does the media favor IOVA or TGTX?

Is IOVA or TGTX more profitable?

Do analysts prefer IOVA or TGTX?

Which has stronger valuation and earnings, IOVA or TGTX?

Which has more volatility and risk, IOVA or TGTX?

Do institutionals and insiders have more ownership in IOVA or TGTX?

Summary

How does Iovance Biotherapeutics compare to Qiagen?

Which has higher earnings and valuation, QGEN or IOVA?

Do insiders and institutionals hold more shares of QGEN or IOVA?

Do analysts recommend QGEN or IOVA?

Does the media refer more to QGEN or IOVA?

Which has more risk and volatility, QGEN or IOVA?

Is QGEN or IOVA more profitable?

Summary

How does Iovance Biotherapeutics compare to Apogee Therapeutics?

Does the media refer more to APGE or IOVA?

Do insiders & institutionals hold more shares of APGE or IOVA?

Is APGE or IOVA more profitable?

Do analysts recommend APGE or IOVA?

Which has more volatility and risk, APGE or IOVA?

Which has preferable valuation and earnings, APGE or IOVA?

Summary

How does Iovance Biotherapeutics compare to Immunovant?

Do institutionals and insiders hold more shares of IMVT or IOVA?

Is IMVT or IOVA more profitable?

Which has stronger earnings & valuation, IMVT or IOVA?

Which has more volatility & risk, IMVT or IOVA?

Does the media refer more to IMVT or IOVA?

Do analysts recommend IMVT or IOVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools